Following up on an article written in 2006, Susan McGoldrick of QCTR Ltd is assessing the state of CNS drug development, looking into what progress has been made since. Has the world in CNS changed? What have been the breakthroughs and the changes for patients, and is the need any closer to being met? Currently, CNS drug sales are dominated by antipsychotics and antidepressants, and despite some leading drugs recently going off-patent, sales of branded drugs are still growing. However, despite the large sales there still remains unmet need for patients.